Çağrı DAMAR, Betül Emine DERİNKUYU, Muazzez Asburçe Bike Olgaç KILIÇKAYA, Mehmet ÖZTÜRK, Çiğdem ÖZTUNALI, Ayşe Gül ALIMLI, Öznur Leman BOYUNAGA, Murat UÇAR, Fatih Süheyl EZGÜ, Leyla TÜMER, Alp Özgün BÖRCEK, Ahmet SIĞIRCI

Posterior fossa horns; a new calvarial finding of mucopolysaccharidoses with well-known cranial MRI features

Background/aim: Mucopolysaccharidoses MPS are a group of hereditary metabolic diseases. The aim of this study was to share the previously unreported calvarial finding of internal hypertrophy of the occipitomastoid sutures IHOMS together with some other well- known cranial MRI findings in this patient series. Materials and methods: A retrospective evaluation was conducted of 80 cranial MRIs of patients who had been diagnosed and followed up with MPS from 2008 to 2019 in our center. Of these patients, 11 had Hurler, 14 had Hunter, 24 had Sanfilippo, 15 had Morquio, 14 had Maroteaux-Lamy, and 2 had Sly disease. The cranial MRIs were assessed in two main groups as parenchymal intradural cranial MRI findings and extradural calvarial findings. Results: The most common parenchymal intradural cranial MRI findings were white matter signal alterations n = 51, 63% and perivascular space enlargements n = 39, 48% . The most common extradural calvarial findings were J-shaped sella n = 45, 56% and tympanic effusion n = 44, 55% . Although IHOMS was defined in a relatively small number of the patients n = 12, 15% , the prevalence rate was high in MPS type I n = 6, 54% . Conclusion: The abnormal cranial MRI findings of the MPS patients, including the newly identified IHOMS, may provide diagnostic clues to differentiate the type of the disease in radiological imaging.

Keywords:

Lysosomal storage diseases, glycosaminoglycans, mucopolysaccharidosis, magnetic resonance imaging, internal hypertrophy of the occipitomastoid sutures,

___

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, ed. The Metabolic and Molecular Bases of Inherited Disease. New York, NY, USA: McGraw-Hill; 2001. pp. 3421-3452.
2. Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 2011; 50 (Suppl 5): v4-12. doi: 10.1093/rheumatology/ker394
3. Coutinho MF, Lacerda L, Alves S. Glycosaminoglycan storage disorders: a review. Biochemistry Research International 2012; 2012. doi: 10.1155/2012/471325
4. Morishita K, Petty RE. Musculoskeletal manifestations of mucopolysaccharidoses. Rheumatology (Oxford) 2011; 50 (Suppl 5): v19-25. doi: 10.1093/rheumatology/ker397
5. Clarke LA. Pathogenesis of skeletal and connective tissue involvement in the mucopolysaccharidoses: glycosaminoglycan storage is merely the instigator. Rheumatology (Oxford) 2011; 50 (Suppl 5): v13-18. doi: 10.1093/rheumatology/ker395
6. Quiney FRE, Amirfeyz R, Smithson S, Gargan M, Monsell F. The mucopolysaccaridoses. Orthopaedics and Trauma 2012; 26 (1): 60-63. doi: 10.1016/j.mporth.2012.01.001
7. Palmucci S, Attinà G, Lanza ML, Belfiore G, Cappello G et al. Imaging findings of mucopolysaccharidoses: a pictorial review. Insights into Imaging 2013; 4 (4): 443-459. doi: 10.1007/ s13244-013-0246-8
8. Clarke LA, Hollak CE. The clinical spectrum and pathophysiology of skeletal complications in lysosomal storage disorders. Best Practice & Research Clinical Endocrinology & Metabolism 2015; 29 (2): 219-235. doi: 10.1016/j. beem.2014.08.010
9. Rasalkar D, Chu W, Hui J, Chu C, Paunipagar B et al. Pictorial review of mucopolysaccharidosis with emphasis on MRI features of brain and spine. The British Journal of Radiology 2011; 84 (1001): 469-477. doi: 10.1259/bjr/59197814
10. Coppa GV. Why should rheumatologists be aware of the mucopolysaccharidoses? Rheumatology (Oxford) 2011; 50 (Suppl 5): v1-3. doi: 10.1093/rheumatology/ker391
11. Summers CG, Ashworth JL. Ocular manifestations as key features for diagnosing mucopolysaccharidoses. Rheumatology (Oxford) 2011; 50 (Suppl 5): v34-40. doi: 10.1093/rheumatology/ker392
12. Giugliani R, Federhen A, Muñoz Rojas MV, Vieira T, Artigalás O et al. Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genetics and Molecular Biology 2010; 33 (4): 589-604. doi: 10.1590/S1415-47572010005000093
13. Zafeiriou DI, Batzios SP. Brain and spinal MR imaging findings in mucopolysaccharidoses: a review. American Journal of Neuroradiology 2013; 34 (1): 5-13. doi: 10.3174/ajnr.A2832
14. Reichert R, Campos LG, Vairo F, de Souza CF, Perez JA et al. Neuroimaging findings in patients with mucopolysaccharidosis: what you really need to know. Radiographics 2016; 36 (5): 1448-1462. doi: 10.1148/rg.2016150168
15. Coppa G, Gabrielli O, Zampini L, Maccari F, Mantovani V et al. Mental retardation in mucopolysaccharidoses correlates with high molecular weight urinary heparan sulphate derived glucosamine. Metabolic Brain Disease 2015; 30 (6): 1343-1348. doi: 10.1007/s11011-015-9684-y
16. Matheus MG, Castillo M, Smith JK, Armao D, Towle D et al. Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation. Neuroradiology 2004; 46 (8): 666-672. doi: 10.1007/s00234-004-1215-1
17. Manara R, Priante E, Grimaldi M, Santoro L, Astarita L et al. Brain and spine MRI features of Hunter disease: frequency, natural evolution and response to therapy. Journal of Inherited Metabolic Disease 2011; 34 (3): 763-780. doi: 10.1007/s10545- 011-9317-5
18. Vedolin L, Schwartz I, Komlos M, Schuch A, Azevedo A et al. Brain MRI in mucopolysaccharidosis: effect of aging and correlation with biochemical findings. Neurology 2007; 69 (9): 917-924. doi: 10.1212/01.wnl.0000269782.80107.fe
19. Parsons V, Hughes D, Wraith J. Magnetic resonance imaging of the brain, neck and cervical spine in mild Hunter’s syndrome (mucopolysaccharidoses type II). Clinical Radiology 1996; 51 (10): 719-723. doi: 10.1016/s0009-9260(96)80246-7
20. Gabrielli O, Polonara G, Regnicolo L, Petroni V, Scarabino T et al. Correlation between cerebral MRI abnormalities and mental retardation in patients with mucopolysaccharidoses. American Journal of Medical Genetics Part A 2004; 125 (3): 224-231. doi: 10.1002/ajmg.a.20515
21. Aydin M, Akarsu S, Kabakus N, Akpolat N. Mucopolysaccharidosis IIIB, cerebral vasculopathy and recurrent subdural hematoma. Indian Pediatrics 2006; 43 (5): 437.
22. Dähnert W. Radiology Review Manual. 7th ed. Philadelphia, PA, USA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011. p. 251.
23. Berger KI, Fagondes SC, Giugliani R, Hardy KA, Lee KS et al. Respiratory and sleep disorders in mucopolysaccharidosis. Journal of Inherited Metabolic Disease 2013; 36 (2): 201-210. doi: 10.1007/s10545-012-9555-1
24. Schumacher RG, Brzezinska R, Schulze-Frenking G, Pitz S. Sonographic ocular findings in patients with mucopolysaccharidoses I, II and VI. Pediatric Radiology 2008; 38 (5): 543-550. doi: 10.1007/s00247-008-0788-y
25. Nicolas-Jilwan M, AlSayed M. Mucopolysaccharidoses: overview of neuroimaging manifestations. Pediatric Radiology 2018; 48 (10): 1503-1520. doi: 10.1007/s00247-018-4139-3
26. Alqahtani E, Huisman TA, Boltshauser E, Scheer I, Gungor T et al. Mucopolysaccharidoses type I and II: new neuroimaging findings in the cerebellum. European Journal of Paediatric Neurology 2014; 18 (2): 211-217. doi: 10.1016/j. ejpn.2013.11.014
27. Oussoren E, Mathijssen IMJ, Wagenmakers M, Verdijk RM, Bredero-Boelhouwer HH et al. Craniosynostosis affects the majority of mucopolysaccharidosis patients and can contribute to increased intracranial pressure. Journal of Inherited Metabolic Disease 2018; 41 (6): 1247-1258. doi: 10.1007/ s10545-018-0212-1
28. Lehman TJ, Miller N, Norquist B, Underhill L, Keutzer J. Diagnosis of the mucopolysaccharidoses. Rheumatology (Oxford) 2011; 50 (Suppl 5): v41-48. doi: 10.1093/ rheumatology/ker390
29. Scarpa M, Orchard PJ, Schulz A, Dickson PI, Haskins ME et al. Treatment of brain disease in the mucopolysaccharidoses. Molecular Genetics and Metabolism 2017; 122s: 25-34. doi: 10.1016/j.ymgme.2017.10.007